Literature DB >> 34218421

The prognostic role of late gadolinium enhancement on cardiac magnetic resonance in patients with nonischemic cardiomyopathy and reduced ejection fraction, implanted with cardioverter defibrillators for primary prevention. A systematic review and meta-analysis.

Ioannis Anagnostopoulos1, Maria Kousta2, Charalampos Kossyvakis2, Eleni Lakka2, Nikolaos Taxiarchis Paraskevaidis2, Nikolaos Schizas3, Nikolaos Alexopoulos4, Spyridon Deftereos5, Georgios Giannopoulos2.   

Abstract

BACKGROUND: Previous studies suggest that late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR) is associated with arrhythmic events in patients with nonischemic cardiomyopathy (NICM), while others have questioned the role of left ventricular ejection fraction (LVEF) as a sole predictor of future events.
OBJECTIVES: To evaluate the role of LGE on CMR in identifying patients with NICM and reduced LVEF for whom a benefit from defibrillator implantation for primary prevention is not anticipated, thus they are mainly exposed to potential risks.
METHODS: Major electronic databases were searched for studies reporting the incidence of appropriate device therapy (ADT), sudden cardiac death (SCD), and cardiac death based on the presence of LGE on CMR, among patients with NICM and reduced LVEF, implanted with a cardioverter defibrillator for primary prevention.
RESULTS: Eleven studies (1652 patients, 947 with LGE) were included in the final analysis. LGE presence was strongly associated with ADT (logOR: 1.95, 95%CI: 1.21-2.69) and cardiac death (logOR: 0.91, 95%CI: 0.14-1.68), but not with SCD (logOR: 0.26, 95%CI: -1.09-1.6). Diagnostic accuracy analysis demonstrated that contrast enhancement is a sensitive marker of future ADT and cardiac death (93%, 95%CI: 85.8-96.7%; 82.9%, 95%CI: 70.6-90.7%; respectively), with moderate specificity ( 44%, 95%CI: 27.2-62.6%; 37.7%, 95%CI: 23.4-54.6%; respectively).
CONCLUSION: LGE is a highly sensitive predictor of ADT and cardiac death in NICM patients implanted with a defibrillator for primary prevention. However, due to moderate specificity, derivation of a cutoff with adequate predictive values and probably a multifactorial approach are needed to improve discrimination of patients who will not benefit from ICDs.
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cardiac death; Cardiac magnetic resonance; Dilated cardiomyopathy; ICD; Implantable cardioverter defibrillator; Nonischemic cardiomyopathy; Prognosis; Sudden cardiac death; Ventricular arrhythmias

Mesh:

Substances:

Year:  2021        PMID: 34218421     DOI: 10.1007/s10840-021-01027-6

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  2 in total

1.  2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.

Authors:  Sana M Al-Khatib; William G Stevenson; Michael J Ackerman; William J Bryant; David J Callans; Anne B Curtis; Barbara J Deal; Timm Dickfeld; Michael E Field; Gregg C Fonarow; Anne M Gillis; Christopher B Granger; Stephen C Hammill; Mark A Hlatky; José A Joglar; G Neal Kay; Daniel D Matlock; Robert J Myerburg; Richard L Page
Journal:  Circulation       Date:  2018-09-25       Impact factor: 29.690

2.  Implantable cardiac defibrillators for people with non-ischaemic cardiomyopathy.

Authors:  Mohamad El Moheb; Johny Nicolas; Assem M Khamis; Ghida Iskandarani; Elie A Akl; Marwan Refaat
Journal:  Cochrane Database Syst Rev       Date:  2018-12-08
  2 in total
  1 in total

1.  CMR - Late gadolinium enhancement characteristics associated with monomorphic ventricular arrhythmia in patients with non-ischemic cardiomyopathy.

Authors:  Priyanka Rajinthan; Kevin Gardey; Sara Boccalini; Salim Si-Mohammed; Arnaud Dulac; Clothilde Berger; Leslie Placide; Antoine Delinière; Nathan Mewton; Philippe Chevalier; Francis Bessière
Journal:  Indian Pacing Electrophysiol J       Date:  2022-08-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.